Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) showcased promising developments in its Phase II clinical trial, ARCHER, during an oral presentation at the World Congress on Acute Heart Failure 2024.
The event provided a platform for Univ.-Prof. Dr. med. Carsten Tschöpe from the Berlin Institute of Health - Charité to present the trial's design, rationale, and initial data on the first 50 patients.
ARCHER, a Phase II randomized, double-blind, placebo-controlled trial, aims to evaluate the efficacy of CardiolRx in enhancing myocardial recovery among patients with acute myocarditis.
With patient recruitment surpassing 85% of the target enrollment, ARCHER has gained momentum, buoyed by increased awareness of myocarditis and strong collaboration among clinical partners. The trial, expected to enroll 100 patients across leading cardiovascular research centers worldwide, employs rigorous primary outcome measures such as cardiac magnetic resonance imaging assessments of left ventricular function and myocardial edema/fibrosis, pivotal in predicting long-term patient prognosis.
Cardiol said that the trial's manuscript has been accepted for publication by ESC Heart Failure, underscoring the significance of the research in advancing knowledge about heart failure globally.
David Elsley, President and CEO of Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL), emphasized the profound interest from the cardiology community in innovative treatments for acute myocarditis, a condition lacking approved therapies by regulatory authorities in Europe and the United States.
"Patient recruitment has been accelerating due in large part to the growing global awareness of myocarditis and the interest and commitment demonstrated by our clinical collaborators and participating patients,” Elsley said in a statement.
Elsley also highlighted the consistency of baseline data from the first 50 patients, reflecting the expected demographics and initial outcomes aligning with acute myocarditis profiles.
In addition to evaluating myocardial function, ARCHER will assess secondary outcomes including left ventricular ejection fraction, survival rates, and changes in biomarkers associated with cardiac function and inflammation.
The information will shed light on the therapeutic potential of CardiolRx, complementing the company's MAvERIC-Pilot Phase II study targeting recurrent pericarditis, with topline results anticipated in early June 2024.